Oramed Pharmaceuticals Inc. (ORMP) - 10-K Summary
Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Oramed is a pharmaceutical company developing oral delivery systems for therapeutic proteins, primarily focusing on oral insulin (ORMD-0801) for Type 2 Diabetes. Following the failure of its Phase 3 trials (ORA-D-013-1 and ORA-D-013-2) in January 2023, the company analyzed data identifying responsive patient subpopulations. In September 2024, it submitted a protocol for a revised Phase 3 trial (ORA-D-013-3) to the FDA, with initiation planned for 2025. The company is also evaluating strategic opportunities, including a Joint Venture (JV) with Hefei Tianhui Biotech Co., Ltd. (HTIT) to form OraTech Pharmaceuticals, Inc.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenues | $0 | $1,340 |
| Net Loss | $(19,103) | $5,088 (Income) |
| Research & Development Expenses | $(6,324) | $(8,971) |
| General & Administrative Expenses | $(6,457) | $(8,425) |
| Financial Income (Expenses), Net | $(2,286) | $22,894 |
| Cash and Cash Equivalents | $54,420 | $9,055 |
| Short-Term Deposits | $55,281 | $95,279 |
| Working Capital | $137,536 | $109,370 |
| Stockholders' Equity | $146,265 | $163,821 |
Note: The 2023 net income was driven by a $22.9 million net financial income, primarily from the revaluation of investments in Scilex Holding Company. In 2024, the company recorded a net financial loss of $2.3 million due to revaluation changes and lower interest income.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in 2024 from $1.34 million in 2023. The 2023 revenue was recognized from the HTIT License Agreement, which was fully recognized through June 2023.
- Profitability Shift: The company swung from a net income of $5.1 million in 2023 to a net loss of $19.1 million in 2024. This was primarily due to the absence of the large financial income gain from Scilex investment revaluation seen in 2023.
- Expense Reduction: R&D expenses decreased by 30% ($2.65 million) and G&A expenses decreased by 23% ($1.97 million), largely due to the termination of Phase 3 trials and reversals of expenses following executive departures.
- Liquidity Improvement: Cash and cash equivalents increased significantly from $9.1 million to $54.4 million, driven by proceeds from short-term deposits and repayments from Scilex under the Tranche A Note.
Guidance, Outlook, and Strategic Developments
Strategic Pivot and Joint Venture: The company is executing a major strategic shift via a Joint Venture Agreement with HTIT to form OraTech.
- OraTech Formation: OraTech will hold Oramed's oral insulin IP and technology.
- Investment: HTIT is committed to investing $40 million (Initial Closing) and $20 million (Second Closing, contingent on Nasdaq listing). Oramed will contribute $7.5 million per closing.
- Spin-Off: The agreement outlines a spin-off of OraTech, distributing the majority of Oramed's shares in OraTech to Oramed shareholders.
- Timeline: Initial Closing is set for April 30, 2025; Second Closing by May 31, 2025 (no later than Sept 1, 2025).
- Tranche A Note: Maturity extended from March 2025 to December 31, 2025. Oramed received 3.25 million Scilex shares as consideration.
- Tranche B Note: Oramed holds $25 million principal. First amortization payment deferred to October 2026.
- Royalties: Oramed secured rights to 4% royalties on Scilex products (ZTlido, SP-103) and 2% on Gloperba/Elyxyb outside the US.
Risks and Contingencies
- Clinical Trial Risk: Success depends on the revised Phase 3 trial (ORA-D-013-3) meeting endpoints in specific subpopulations. Failure would jeopardize the core business value.
- JV Execution Risk: The OraTech spin-off and closings are subject to regulatory approvals and Nasdaq listing. Failure to close could harm financial position.
- Scilex Credit Risk: A significant portion of assets is tied to Scilex notes and warrants. Scilex has disclosed substantial doubt about its ability to continue as a going concern.
- Regulatory & Geopolitical: Operations in Israel expose the company to regional conflict risks. Regulatory approval for oral insulin remains uncertain.
- Investment Company Status: Significant holdings in securities (Scilex, BioXcel, DNA, Entera) and real estate raise the risk of being deemed an investment company under the 1940 Act.
Key Facts for Investor Verification
- Phase 3 Trial Status: Verify the FDA acceptance and initiation timeline of the ORA-D-013-3 protocol submitted in September 2024.
- OraTech Closing Conditions: Monitor the April 30, 2025 Initial Closing and the Nasdaq listing requirement for the Second Closing.
- Scilex Solvency: Assess Scilex's ability to service the Tranche A and B notes, given their "going concern" disclosure.
- Real Estate Commitments: Track the deployment of the approved $30 million real estate investment budget and associated returns.
- IIA Obligations: Confirm the February 2025 payment of ~$2 million to the Israel Innovation Authority (IIA) cleared all royalty obligations.